• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    FIGS (FIGS) Beat Q2 Earnings Estimates, Is The Stock Already Trading At A Premium?

    Simply Wall St·09/02/2026 16:28:11
    语音播报

    FIGS stock reaction after Q2 earnings beat

    FIGS (FIGS) recently reported Q2 earnings that exceeded expectations, an outcome that has drawn fresh attention to the stock. Investors are now reassessing the healthcare apparel company’s growth profile and valuation after the surprise result.

    The Q2 beat helped extend a strong run for FIGS, with a 30-day share price return of 42.62% and a year-to-date share price return of 33.98%. At the same time, the 1-year total shareholder return of 127.42% is being weighed against longer-term performance, including a 5-year total shareholder return that is down 66.22%.

    Compare FIGS' post earnings momentum with a curated group of healthcare and quality consumer stocks by scanning the 74 resilient stocks with low risk scores that aim to balance upside potential with more resilient profiles.

    After a month when FIGS surged and short term returns reset sharply higher, the question now is whether the current valuation still leaves enough upside to justify the risk buyers would be taking from here.

    Most Popular Narrative: 6% Overvalued

    Based on the most followed FIGS narrative, the fair value estimate of $14.39 sits below the recent close of $15.26. This frames the latest earnings reaction in a different light.

    The company, on an absolute basis, is still growing well. Further, it has several growth levers, such as expanding its product range, entering new markets, and leaning into its “TEAMS” offering.

    Read the complete narrative. Read the complete narrative.

    Want to understand why this growth story still only supports a mid teens valuation? The narrative leans heavily on brand strength, margin expansion, and a richer product mix. It is worth considering how those assumptions translate into the discount rate and long term growth profile reflected in that $14 handle.

    Result: Fair Value of $14.39 (OVERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, FIGS still faces clear risks, including pressure on premium pricing if economic conditions weigh on healthcare spending, and potential setbacks in executing its international and TEAMS expansion.

    Find out about the key risks to this FIGS narrative.

    Next Steps

    If this mix of optimism and caution around FIGS feels familiar, consider it a prompt to check the numbers yourself and stress test the assumptions. To see which factors investors are currently most positive about in the FIGS story, review the 3 key rewards

    Looking for more FIGS investment ideas?

    If FIGS has sharpened your focus, do not stop here. Broaden your watchlist with curated stock ideas that match different risk and return profiles using the Simply Wall St screener.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.